Jennifer Buell, President and Chief Executive Officer of MiNK Therapeutics and Executive Council at Agenus, shared a post on X:
“MSS colon cancer has long resisted immunotherapy.;
BOTENSILIMAB is changing this:
- 29% pCR in (UNICORN).
- 100% RFS at 18.2 mos (NEST).
- 19% ORR in r/r mCRC.
- 71% ORR w/ chemo + targeted Tx in 1L CRC.”
More updates on Botensilimab.